S. Yang, C. E. Vervaert, J. Burch, Jr., J. Grichnik, H. F. Siegler and T. L. Darrow, “Murine Dendritic Cells Transfected with Human gp100 Elicit Both Antigen-Specific CD8+ and CD4+ T-Cell Responses and Are More Effective than DNA Vaccines at Generating Anti-Tumor Immunity,” International Journal of Cancer, Vol. 83, No. 4, 1999, pp. 532-540. doi:10.1002/(SICI)1097-0215(19991112)83:4<532::AID-IJC16>3.0.CO;2-K

has been cited by the following article:

• TITLE: Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses

  AUTHORS: Kristian M. Hargadon

  KEYWORDS: Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.3 No.2A, June 20, 2013

  ABSTRACT: Melanoma is the most aggressive form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Its ability to metastasize quickly, often before diagnosis, makes this cancer difficult to treat with traditional therapies. The identification of anti-melanoma immune responses in patients and the discovery of tumor antigens targeted by these immune responses have paved the way for immunotherapy as a novel approach to treating this cancer. In this review, the major immunotherapies targeting these melanoma tumor antigens are discussed. The advantages and limitations of peptide-, protein-, and gene-based vaccination maneuvers and adoptive cell transfer therapies are emphasized. Recent insights into melanoma immune evasion strategies are also highlighted, with particular focus on how our increasing knowledge of tumor/immune cell interactions is driving the development of novel immunotherapeutic strategies for the treatment of melanoma.